Month: December 2020

The Supreme Court ruled in supportive of public health policy in olanzapine patent dispute

In Olanzapine patent disputes, the Supreme Court ruled as we claimed. See, decision in Lilly Korea v. Hanmi and decision in Lilly Korea v. Myung-In (all in Korean). The Court did not recognize that generic companies are liable for the reduction of upper price limit of patented product, Zyprexa (Olanzapine) even when the reduction was …